{"id":33017,"date":"2020-08-11T12:11:12","date_gmt":"2020-08-11T11:11:12","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=33017"},"modified":"2023-04-30T22:15:46","modified_gmt":"2023-04-30T21:15:46","slug":"catherine-larue","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/catherine-larue\/","title":{"rendered":"Catherine Larue"},"content":{"rendered":"<div class=\"vgblk-rw-wrapper limit-wrapper\">\n\n\t<h2>Catherine Larue<\/h2>\n<h4>\u00a0CEO at IBBL<\/h4>\n\t<p>After a Ph.D. in Immunology, Catherine Larue began her career at Sanofi, Montpellier (France) in the cardiovascular R&amp;D department and participated in the discovery of innovative biomarkers such as troponin I and natriuretic peptides.<\/p>\n<p>She then joined Sanofi Diagnostics Pasteur, at Minneapolis MN (USA) for 3 years where she was responsible for Assay Development in the immunodiagnostic area. She completed an Executive MBA in 2003 and had worked for 7 years as a Director of Business Unit at Bio-Rad. After installing the Biomarkers department in Genfit (Lille, France), she took over the CEO position of the Institute IBBL (Integrated Biobank of Luxembourg) in 2012. She is an author of 87 publications and filed 13 patents.<\/p>\n<p>She served in standardisation committees on Cardiovascular Biomarkers at AACC and IFCC for 15 years; she also created and chaired the &#8220;Biomarkers Group&#8221; in the Competitiveness Bio-cluster (Medicen, Paris). She is currently serving as an expert for the European Commission (H2020 and IMI programmes) and for the first Luxembourg Plan Cancer.<\/p>\n\t\t\t\t\t\t\t<img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit_2.jpg\" alt=\"Catherine_Larue_IBBL_BioTech_Pharma_Summit_2\" itemprop=\"image\" height=\"1224\" width=\"820\" title=\"Catherine_Larue_IBBL_BioTech_Pharma_Summit_2\" onerror=\"this.style.display='none'\"  sizes=\"auto, (max-width: 768px) 100vw, 100vw\" srcset=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit_2-201x300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit_2-686x1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit_2-768x1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit_2-630x940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit_2-420x627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit_2-315x470.jpg 315w\" \/>\t\t\t\t\t\t\t\n<h3>\n\tTitle: How research infrastructures can efficiently contribute to translational\/personalised medicine?\n\t<\/h3>\n<ul>\n<li>Which research infrastructures are making an impact?<\/li>\n<li>Impact of the integration of research infrastructures on translational and personalised medicine<\/li>\n<li>Building bridges between academic research and health industry, for a better European translational and personalised medicine<\/li>\n<\/ul>\n\t<a href=\"https:\/\/sociopharma.com\/\" target=\"_blank\" role=\"button\" rel=\"noopener\">\n\t\t\t\t\tPresentation available only at SocioPharma.com\n\t<\/a>\n<h4>\n\t\t\t<a href=\"#\" title=\"On the Web\" target=\"_self\" rel=\"noopener\">\n\tOn the Web\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.ibbl.lu\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.ibbl.lu\/<\/a><\/p>\n<h4>\n\t\t\t<a href=\"#\" title=\"On LinkedIn\" target=\"_self\" rel=\"noopener\">\n\tOn LinkedIn\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.linkedin.com\/in\/catherine-larue-164b8a4\/\" target=\"_blank\" rel=\"noopener\">Visit Profile<\/a><\/p>\n\n<\/div><!-- .vgblk-rw-wrapper -->","protected":false},"excerpt":{"rendered":"<p>Catherine Larue \u00a0CEO at IBBL After a Ph.D. in Immunology, Catherine Larue began her career at Sanofi, Montpellier (France) in the cardiovascular R&amp;D department and participated in the discovery of innovative biomarkers such as troponin I and natriuretic peptides. She then joined Sanofi Diagnostics Pasteur, at Minneapolis MN (USA) for 3 years where she was&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33018,"parent":33015,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-33017","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Catherine Larue &#8226; BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"After a Ph.D. in Immunology, Catherine Larue began her career at Sanofi, Montpellier (France) in the cardiovascular R&amp;D department and participated in the discovery of innovative biomarkers such as troponin I and natriuretic peptides.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/catherine-larue\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Catherine Larue &#8226; BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"After a Ph.D. in Immunology, Catherine Larue began her career at Sanofi, Montpellier (France) in the cardiovascular R&amp;D department and participated in the discovery of innovative biomarkers such as troponin I and natriuretic peptides.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/catherine-larue\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-30T21:15:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/catherine-larue\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/catherine-larue\/\",\"name\":\"Catherine Larue &#8226; BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/catherine-larue\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/catherine-larue\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit.jpg\",\"datePublished\":\"2020-08-11T11:11:12+00:00\",\"dateModified\":\"2023-04-30T21:15:46+00:00\",\"description\":\"After a Ph.D. in Immunology, Catherine Larue began her career at Sanofi, Montpellier (France) in the cardiovascular R&D department and participated in the discovery of innovative biomarkers such as troponin I and natriuretic peptides.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/catherine-larue\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/catherine-larue\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/catherine-larue\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit.jpg\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit.jpg\",\"width\":900,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/catherine-larue\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biobanking 2019 Speakers\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Catherine Larue\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow&#039;s healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Catherine Larue &#8226; BioTech Pharma Summit","description":"After a Ph.D. in Immunology, Catherine Larue began her career at Sanofi, Montpellier (France) in the cardiovascular R&D department and participated in the discovery of innovative biomarkers such as troponin I and natriuretic peptides.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/catherine-larue\/","og_locale":"en_US","og_type":"article","og_title":"Catherine Larue &#8226; BioTech Pharma Summit","og_description":"After a Ph.D. in Immunology, Catherine Larue began her career at Sanofi, Montpellier (France) in the cardiovascular R&D department and participated in the discovery of innovative biomarkers such as troponin I and natriuretic peptides.","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/catherine-larue\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2023-04-30T21:15:46+00:00","og_image":[{"width":900,"height":900,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/catherine-larue\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/catherine-larue\/","name":"Catherine Larue &#8226; BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/catherine-larue\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/catherine-larue\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit.jpg","datePublished":"2020-08-11T11:11:12+00:00","dateModified":"2023-04-30T21:15:46+00:00","description":"After a Ph.D. in Immunology, Catherine Larue began her career at Sanofi, Montpellier (France) in the cardiovascular R&D department and participated in the discovery of innovative biomarkers such as troponin I and natriuretic peptides.","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/catherine-larue\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/catherine-larue\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/catherine-larue\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit.jpg","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Larue_IBBL_BioTech_Pharma_Summit.jpg","width":900,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/catherine-larue\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Biobanking 2019 Speakers","item":"https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/"},{"@type":"ListItem","position":3,"name":"Catherine Larue"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow&#039;s healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33017","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=33017"}],"version-history":[{"count":5,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33017\/revisions"}],"predecessor-version":[{"id":38256,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33017\/revisions\/38256"}],"up":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33015"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/33018"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=33017"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}